Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11174169 | 0.80 | CA12 (0.67) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3077426 | 0.78 | CA12 (0.64) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3452601 | 0.76 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10742919 | 0.76 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10742927 | 0.76 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3071219 | 0.76 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL365772 | 0.76 | EPHX2 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6631354 | 0.75 | HTT (0.36) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6060070 | 0.74 | CA12 (0.95) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3772058 | 0.74 | CA12 (0.95) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-2266978-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7619100-B2 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7550503-B2 | Physiologically active substances | EISAI R& D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | KOTAKE YOSHIHIKO | 2008-11-06 | — | — | US | disclosed |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20060241171-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-4118378-A | THIURAM SULFIDES OF OXAZOLIDINES AND THIAZOLIDINES | PENNWALT CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4099003-A | NON-BLOOMING ACCELERATOR AND PROCESS FOR VULCANIZATION OF EPDM ELASTOMERS | PENNWALT CORPORATION (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, HDAC1, HDAC3 | CA12 857/4885CA1 2480/4885CA2 3365/4885 |
| US-20050245514-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CA12 235/4885CA1 174/4885CA2 100/4885 |
| US-20060241171-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CA12 407/4885CA1 189/4885CA2 112/4885 |
| US-20060009439-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | CA12 407/4885CA1 189/4885CA2 112/4885 |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | CA12 407/4885CA1 189/4885CA2 112/4885 |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC1 | CA12 834/4885CA1 2669/4885CA2 3443/4885 |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | CA12 407/4885CA1 189/4885CA2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.